Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)

The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ryo Goto, Kenya Kamimura, Yoko Shinagawa‐Kobayashi, Norihiro Sakai, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Hiroshi Nishina, Shuji Terai
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2019-04-01
Col·lecció:	FEBS Open Bio
Matèries:	d‐rR/Tokyo medaka liver fibrosis NASH SGLT2 tofogliflozin
Accés en línia:	https://doi.org/10.1002/2211-5463.12598
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!